| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3987905 | European Journal of Surgical Oncology (EJSO) | 2006 | 6 Pages |
Abstract
The combination of gemcitabine and docetaxel for chemotherapy in unresectable pancreatic carcinoma was well tolerated. Survival time and 1-year survival rate proved promising and the regimen appears suitable for further evaluation in a prospective phase-III study setting.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K. Ridwelski, J. Fahlke, R. Kuhn, A. Hribaschek, E. Kettner, C. Greiner, A. Florschuetz, T. Manger, G. Wilhelm, H. Klein, S. Hahnfeld, H. Lippert, F. Meyer,